Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMA
NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA
NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA) and reminds investors of the January 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 10, 2024, and October 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before January 17, 2025.
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming Deadlines - HUMA
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman
HUMA Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2024 / Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company misled investors about the status of its key product and the regulatory compliance of its manufacturing facilities. Hagens Berman urges investors in Humacyte (NASDAQ:HUMA) who suffered substantial losses to submit your losses now.
